Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
696
datasets available to search
ShareScore release 0.9.0
Dataset results
696 results for “Adrenal”
Cholesterol deprivation drives DHEA biosynthesis in human adrenals
GEO Series GSE191180. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
Affymetrix SNP6 array data for ACTH-Independent Macronodular Adrenal Hyperplasia (AIMAH) samples
GEO Series GSE42171. Homo sapiens. 52 samples. Type: Genome variation profiling by SNP array; SNP genotyping by SNP array.
Transcriptome Profiling for human Leydig cell-like cells, adrenal cell-like cells, and induced pluripotent stem cells
GEO Series GSE127915. Homo sapiens. 9 samples. Type: Expression profiling by array.
Influence of form of Se supplementation and tall fescue endophyte toxicity on the adrenal gland transcriptome of grazing beef steers
GEO Series GSE198583. Bos taurus. 32 samples. Type: Expression profiling by array.
Hormonal Regulation of MicroRNA Expression in Rat Adrenal Gland
GEO Series GSE47131. Rattus norvegicus; synthetic construct. 12 samples. Type: Expression profiling by array.
Human Adrenal Cortex affected by Primary Pigmented Nodular Adrenocortical Disease
GEO Series GSE2055. Homo sapiens. 2 samples. Type: Expression profiling by SAGE.
Dataset related to article "Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis "
<p>This record contains raw data related to article “Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis"</p> <p> </p> <p>Adrenal metastases occur in 15-35% of oncological patients. Surgery is the first treatment option. Stereotactic body radiotherapy (SBRT) has been largely explored in oligometastatic patients unfit for surgery, representing an effective and non-invasive local treatment. The results of a multi-institutional experience of SBRT on adrenal metastases in the oligorecurrent or oligoprogressive setting are herein reported. We collected data of adrenal gland metastases treated with SBRT in three Italian centers from 2010 to 2020. End-points of the present study were: Overall survival (OS), Local control of treated metastases (LC), Progression free survival (PFS), and toxicity. 149 adrenal gland metastases were treated with SBRT in 142 patients. The most common primary tumor was lung cancer (58.4%), followed by kidney cancer (9.4%). Median lesion's volume was 28.5 cm<sup>3</sup> (2.5-323.4). The median SBRT dose was 40 Gy (10-60). Median follow-up was 14.4 months. One- and two-year OS were 72.3% and 53.5%. At univariate analysis performance status correlated with survival (HR 1.57, p = 0.006). One- and two-year LC were 85.4% and 79.2%, with lung primary tumor (HR 0.33, p = 0.021) and BED10 (HR 0.97, p = 0.036) significant independent factors. One- and two-year PFS were 37.7% and 24.8%. Median time to polymetastatic disease was 11.3 months. Grade 1 and 2 toxicity occurred in 21 (14.7%) and 3 (2.1%) patients. The results from this large multi-center study confirm the efficacy and safety of SBRT in the management of adrenal gland metastases, as a valid alternative to other more invasive local approaches.</p>
Dataset related to article "Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production "
<p>This record contains raw data related to article "Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production"</p> <p><strong>Purpose: </strong> The purpose of this study was to assess prospectively the efficacy and safety of stereotactic body radiation therapy (SBRT) for adrenal gland metastasis, with a focus on the assessment of the irradiated subjects' endocrinological function.</p> <p><strong>Materials and methods: </strong> A total of 36 patients were enrolled from 2017 to 2020 in this prospective phase II trial. Patients were treated with Linac-based SBRT, with a dose of 45 Gy in 3 consecutive fractions. Primary end-point was local control (LC) of the treated lesions and secondary end-points included evaluation of acute and late toxicity, progression free survival (PFS), overall survival (OS) and the impact on the hormonal production of adrenal glands.</p> <p><strong>Results: </strong> With a median follow-up of 9.5 months, LC rates at 1 and 2 years were 94.7% and 88.4%, respectively. Rates of PFS at 1 and 2 years were 50.5% and 29.8%, with a median PFS of 14.7 months. Rates of OS at 1 and 2 years were 62.9% and 44.1%. At univariate analysis, oligorecurrence was associated with better OS compared to oligoprogressive or synchronous metastatic disease. No grade 3 or greater toxicities were registered and only a minority of patients (22.2%) reported mild treatment-related side effects. Hormonal and electrolytes production was assessed before and after treatment, showing only a slight and transient variation within the reference ranges.</p> <p><strong>Conclusion: </strong> SBRT on adrenal metastases has been confirmed to be a feasible and effective treatment. With an excellent disease control and the preservation of the endocrine function, SBRT with ablative dose can be considered a viable alternative to more invasive approaches.</p>
Influence of form of Se supplementation and tall fescue endophyte toxicity on the adrenal gland and kidney transcriptome of grazing beef steers
GEO Series GSE198589. Bos taurus. 64 samples. Type: Expression profiling by array.
Expression data from mouse adrenal gland at 2 month of age
GEO Series GSE194211. Mus musculus. 4 samples. Type: Expression profiling by array.
The effect of Crem absence on gene expression in mouse adrenal glands.
GEO Series GSE29592. Mus musculus. 10 samples. Type: Expression profiling by array.
The dual nature of hypothalamic-pituitary-adrenal axis regulation in dyads of very preterm infants and their mothers
<p>Raw data of the study "The dual nature of hypothalamic-pituitary-adrenal axis regulation in dyads of very preterm infants and their mothers" In this study, 3-month-old (corrected age) VPT infants and FT counterparts with their mothers took part in a well-validated stress-inducing laboratory task (i.e., double Face-to-Face Still-Face, FFSF paradigm). Salivary cortisol samples were obtained before (Baseline) and after (Early reactivity, Late reactivity and Recovery) the FFSF procedure. Dyadic HPA axis co-regulation was assessed at each sample time-point (i.e., <em>in-moment</em> coupling) as well as across samples (i.e., <em>in-time synchrony</em>). Significant <em>in-moment</em> coupling emerged at Baseline, Late reactivity and Recovery for FT infants’ dyads only. An overlying pattern of salivary cortisol trajectories emerged between mothers and infants in the VPT group, whereas a more complex pattern of reciprocal and complementary co-regulation was found for FT infants’ dyads. Although both groups gave evidence of HPA axis co-regulation, dyads of VPT infants appear to be less able to adapt reciprocally and dynamically to stressful conditions</p>
Mental Health in Patients With Adrenal Incidentalomas: Is There a Relation With Different Degrees of Cortisol Secretion?
<p>Dataset for the paper Mental Health in Patients With Adrenal Incidentalomas: Is There a Relation With Different Degrees of Cortisol Secretion? </p>
The degree of cortisol secretion is associated with diabetes mellitus and hypertension in patients with nonfunctioning adrenal tumors
<p>This is a database used for a retrospective observational study, about patients with nonfuncioning adrenal tumors. We recorded the available clinical and biochemical data of all patients with adrenal incidentalomas and without mild autonomous cortisol secretion referred to the participating centres from December 2003 to December 2021.</p>
Effects of the therapy shift from cortisone acetate to modified-release hydrocortisone in a group of patients with adrenal insufficiency
<p>Patients with adrenal insufficiency (AI) may be exposed to supraphysiological glucocorticoids levels during standard treatment with cortisone acetate (CA) or immediate-release hydrocortisone (IR-HC). Recent studies, predominantly including patients in IR-HC treatment, suggested that modified-release hydrocortisone (MRH) provide a more physiological cortisol rhythm, improving metabolic control and quality of life. Our primary aim was to assess clinical and biochemical modifications in patients shifted from CA to MRH.</p> <p>We designed a retrospective longitudinal study, enrolling 45 AI patients (22 primary and 23 secondary AI) treated exclusively with CA thrice daily, shifted to MRH once daily; 29/45 patients concluded at least 18-months follow-up (MRH-group). We recruited 35 AI patients continuing CA as a control group (CA-group). Biochemical and clinical data, including metabolic parameters, bone quality, and symptoms of under- or overtreatment were collected. In 24 patients, a daily salivary cortisol curve (SCC) performed before and one month after shifting to MRH was compared to healthy subjects (HS).</p> <p>No significant changes in glycometabolic and bone parameters were observed both in MRH and CA-groups during a median follow-up of 35 months. A more frequent decrease in blood pressure values (23.1% vs 2.8%, p=0.04) and improvement of under- or overtreatment symptoms were observed in MRH vs CA-group. The SCC showed a significant steroid overexposure in both CA and MRH-groups compared to HS [AUC (area under the curve) = 74.4 ± 38.1 nmol×hr/L and 94.6 ± 62.5 nmol×hr/L respectively, vs 44.1 ± 8.4 nmol×hr/L, p<0.01 for both comparisons], although SCC profile was more similar to HS in MRH-group.</p> <p>In our experience, patients shifted from CA to equivalent doses of MRH do not show significant glycometabolic modifications but blood pressure control and symptoms of over-or undertreatment may improve. The lack of amelioration in glucose metabolism and total cortisol daily exposure could suggest the need for a dose reduction when shifting from CA to MRH, due to their different pharmacokinetics.</p>
Prevalence and clinical features of armadillo repeat-containing 5 mutations carriers in a single center cohort of patients with bilateral adrenal incidentalomas
<p>Our work provides interesting information both for the finding of a high prevalence of germline armadillo repeat-containing 5 (ARMC5) pathogenic variants in patients with bilateral adrenal incidentalomas and mild autonomous cortisol secretion and, above all, for the novel detection of somatic mutations in the adrenal tissue of patients without germline ARMC5 pathogenic variants. Although the sample size of our cohort is quite small, due to the monocentric nature of the study, a thorough genetic analysis was performed associated with an extensive hormonal, clinical, and comorbidity assessment. We think that these findings can stimulate in the future further studies to elucidate the pathophysiological role of somatic ARMC5 variants in the adrenal tumor development in otherwise wild-type patients and the possible clinical implications.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.